Developer docs
API playgroundTry for free, no card

Search company profiles

Avacta Group

Full company profile

uuid000at6x

Namestring
Avacta Group
Legal namestring
Avacta Life Sciences Limited
Websiteurl
avacta.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Avacta Group plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing tumor-activated peptide drug conjugates (PDCs) for oncology. Following the 2025 divestiture of its diagnostics businesses (Launch Diagnostics for £12.9M and Coris Bioconcept for £2.15M), the company operates as a pure-play oncology therapeutics business. Its proprietary pre|CISION® platform links a peptide to an existing cancer drug to inactivate it; the peptide is cleaved only by fibroblast activation protein (FAP), which is expressed in approximately 90% of solid tumors, allowing payload release exclusively at the tumor site while the conjugate remains inert in systemic circulation. The Affimer® platform — a ~15kDa protein scaffold derived from stefin A — provides a complementary technology for engineered biotherapeutics and Affimer-drug conjugates (AffDC), with advantages over antibodies including smaller size, higher stability, and the ability to bind difficult targets such as GPCRs.

The clinical pipeline includes AVA6000 (faridoxorubicin, Gen One doxorubicin PDC) in Phase 1a/1b with reported favorable cardiac safety enabling removal of the lifetime maximum dose limit; AVA6103 (FAP-Exd, Gen Two sustained-release exatecan PDC) in the Phase 1 FOCUS-01 trial with first patient dosed in March 2026; preclinical AVA6207 (Gen Three dual-payload PDC); and earlier-stage AVA7100 (AffDC) and AVA3996 (FAP-α-activated proteasome inhibitor). Preclinical data for AVA6103 reportedly shows one-log higher maximal tumor concentration and nearly 3x the Tumor Selectivity Index of Enhertu®. The company is generating negligible product revenue (FY2025 Therapeutics revenue of £0.11M) and recorded a £37.06M loss from continuing operations. Its commercial model is pre-commercial: Phase 1 trials are conducted at specialist US oncology centers (Virginia Cancer Specialists, NEXT Oncology, START Midwest) and management is exploring pharmaceutical partnership opportunities and a potential NASDAQ dual listing to support future commercialization. The company holds 19 patent families across 11 jurisdictions and has raised approximately £41.5M over the past 18 months through equity placements and a convertible bond, with cash balances of £16.9M at year-end 2025.

Avacta serves two primary customer segments: (1) oncology patients with advanced solid tumors — including pancreatic, cervical/vulvar, gastric/GEJ, small cell lung, salivary gland, and soft tissue sarcoma cancers — who have exhausted standard treatment options and stand to benefit from targeted chemotherapy with reduced systemic toxicity; and (2) large pharmaceutical companies that may license or co-develop pre|CISION®-enabled candidates for broader commercialization. The go-to-market motion is enterprise field sales in nature, conducted via specialist clinical trial sites and through investor and scientific conference engagement (AACR, ESMO, EORTC-NCI-AACR, TD Cowen Healthcare Conference). Strategic collaboration with Tempus AI supports biomarker-driven indication selection, while intellectual property comprises 19 patent families covering both core platforms and program-specific applications.

Short descriptiontext

Avacta Group plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing tumor-activated peptide drug conjugates for oncology using its proprietary pre|CISION® and Affimer® platforms. It targets advanced solid tumor patients through Phase 1 trials at US specialist oncology centers, with future revenue dependent on pharmaceutical licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWetherby, United Kingdom
HQ citystring
Wetherby
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide drug conjugates, oncology drug development, tumor-activated therapeutics, biopharmaceutical pipeline, targeted cancer therapy
Industry3 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutics R&D
TypeSubscription Recurring
Description

Pre-revenue clinical stage company. Generated £0.11 million in revenue from Therapeutics division in FY2025. Currently focused on advancing clinical pipeline through Phase 1 trials.

globenewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1pre|CISION
Description

Tumor-activated drug delivery platform that enables precise delivery of cytotoxic payloads directly to tumors, reducing systemic toxicity

avacta.com
+4 more records
Core offering1 text field

Avacta Group plc is a clinical-stage biopharmaceutical company developing oncology therapeutics based on two proprietary platforms: pre|CISION®, a tumor-activated drug delivery system that releases payloads at tumor sites via FAP cleavage, and Affimer®, a ~15kDa protein scaffold used for targeted biotherapeutics and drug conjugates. The pipeline consists of peptide drug conjugates including AVA6000 (doxorubicin PDC, Phase 1b), AVA6103 (exatecan PDC, Phase 1 FOCUS-01), and pre-clinical programs AVA6207 (dual payload), AVA7100 (AffDC), AVA3996 (proteasome inhibitor PDC), and AVA032 (Affimer-IL-15).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Nearly 3x higher Tumor Selectivity Index (TSI) compared to Enhertu® in preclinical studies
+3 more records
Product overview1 text field

Avacta Group is a pure-play oncology biopharmaceutical company developing a pipeline of peptide drug conjugates (PDCs) powered by two proprietary technology platforms: pre|CISION® and Affimer®. The pre|CISION® platform is a tumor-activated drug delivery technology that releases payloads exclusively at tumor sites via FAP enzyme cleavage. The Affimer® platform provides small protein scaffolds for biotherapeutic development. The current clinical pipeline includes Gen One AVA6000 (faridoxorubicin) in Phase 1b, Gen Two AVA6103 (FAP-Exd) in Phase 1, and Gen Three AVA6207 (dual payload) in pre-clinical development. Additional programs include AVA7100 and AVA3996. The company previously operated a diagnostics division (Launch Diagnostics and Coris Bioconcept) which has been divested as part of the transition to a pure-play therapeutics company.

Product and service1 record
1pre|CISION® Platform
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
13B BlackBio Dx Ltd
Strategic tierMinorTypeOthersAnnounced on2025-08-29
Description

Buyer of Coris Bioconcept SRL for £2.15 million upfront consideration with additional earn-out up to £0.615 million. Completion took place on August 29, 2025.

avacta.com
Strategic tierMinorTypeOthersAnnounced on2025-03-25
Description

Buyer of Launch Diagnostics Holdings Limited for £12.9 million. Completion took place in March 2025. Duomed is a subsidiary of Palex Healthcare Group S.L.U.

3Tempus AI
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-30
Description

Strategic collaboration using Tempus AI's data mining capabilities to investigate gene co-expression patterns (SLFN11 and FAP) for predicting cancer patient sensitivity to pre|CISION®-enabled therapies. This AI approach was used to select initial cancer indications for the FOCUS-01 Phase 1 trial of AVA6103.

avacta.com
4Medusa Healthcare (Medusa 19 Healthcare)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-12-22
Description

Exclusive arrangement with Medusa to commercialize the AffiDX® SARS-CoV-2 antigen lateral flow self-test product globally under the brand name MeduFlow. Medusa obtained CE mark for consumer self-testing.

avacta.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pyxis Oncology is a clinical-stage ADC company developing novel antibody-drug conjugates for solid tumors. It directly competes with Avacta's pre|CISION platform in the oncology targeted payload delivery space.

TypeDirect peer
Description

Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs) — a novel ADC-like platform that pairs tumor-targeted delivery with immune activation. As a clinical-stage platform oncology company, it overlaps with Avacta's strategy of using targeted delivery to enhance therapeutic index.

TypeBroad incumbent
Description

AbCellera is a large clinical-stage biologics discovery company with a proprietary antibody platform. While broader in scope, its technology platform approach (engineered antibodies for therapeutic applications) is comparable to Avacta's Affimer platform.

TypeEmerging player
Description

ProfoundBio is an early-stage ADC company developing next-generation conjugates with novel payloads and linkers. As a private oncology platform peer, it represents an emerging competitor in the targeted cancer therapy space.

TypeDirect peer
Description

Mersana develops next-generation ADCs using its Dolasynthen and Immunosynthen platforms, competing directly with Avacta's pre|CISION in oncology payload delivery. Both are clinical-stage oncology platform companies targeting solid tumors.

TypeBroad incumbent
Description

Daiichi Sankyo is the global ADC leader with Enhertu (the benchmark Avacta uses for preclinical comparison). Its DXd ADC platform and deep oncology commercial infrastructure represent the dominant competitive force in the ADC market.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide drug conjugates (BCAs), a peptide-based targeted therapy platform analogous to Avacta's pre|CISION. Both companies use peptide scaffolds to deliver cytotoxic payloads with tumor selectivity, making them the closest direct peers in the PDC space.

TypeDirect peer
Description

ADC Therapeutics is a clinical and commercial-stage ADC company with Zynlonta approved for lymphoma and multiple pipeline candidates. It represents a directly competing ADC platform in the broader oncology drug conjugate space.

TypeDirect peer
Description

CytomX develops Probody therapeutics, a conditionally activated antibody platform that is masked until activated by tumor-associated proteases. This shares Avacta's core concept of tumor-activated drug delivery, though using antibodies rather than peptides.

10Ambrx Biopharma
TypeDirect peer
Description

Ambrx develops engineered antibody-drug conjugates using site-specific conjugation and novel payloads. Its platform approach to ADC development with engineered biologics is comparable to Avacta's AffDC (Affimer drug conjugate) strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avacta Group

Oncology Biopharmaceuticalsavacta.com

Avacta Group plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing tumor-activated peptide drug conjugates for oncology using its proprietary pre|CISION® and Affimer® platforms. It targets advanced solid tumor patients through Phase 1 trials at US specialist oncology centers, with future revenue dependent on pharmaceutical licensing partnerships.

What Avacta Group does

Avacta Group plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing tumor-activated peptide drug conjugates (PDCs) for oncology. Following the 2025 divestiture of its diagnostics businesses (Launch Diagnostics for £12.9M and Coris Bioconcept for £2.15M), the company operates as a pure-play oncology therapeutics business. Its proprietary pre|CISION® platform links a peptide to an existing cancer drug to inactivate it; the peptide is cleaved only by fibroblast activation protein (FAP), which is expressed in approximately 90% of solid tumors, allowing payload release exclusively at the tumor site while the conjugate remains inert in systemic circulation. The Affimer® platform — a ~15kDa protein scaffold derived from stefin A — provides a complementary technology for engineered biotherapeutics and Affimer-drug conjugates (AffDC), with advantages over antibodies including smaller size, higher stability, and the ability to bind difficult targets such as GPCRs.

The clinical pipeline includes AVA6000 (faridoxorubicin, Gen One doxorubicin PDC) in Phase 1a/1b with reported favorable cardiac safety enabling removal of the lifetime maximum dose limit; AVA6103 (FAP-Exd, Gen Two sustained-release exatecan PDC) in the Phase 1 FOCUS-01 trial with first patient dosed in March 2026; preclinical AVA6207 (Gen Three dual-payload PDC); and earlier-stage AVA7100 (AffDC) and AVA3996 (FAP-α-activated proteasome inhibitor). Preclinical data for AVA6103 reportedly shows one-log higher maximal tumor concentration and nearly 3x the Tumor Selectivity Index of Enhertu®. The company is generating negligible product revenue (FY2025 Therapeutics revenue of £0.11M) and recorded a £37.06M loss from continuing operations. Its commercial model is pre-commercial: Phase 1 trials are conducted at specialist US oncology centers (Virginia Cancer Specialists, NEXT Oncology, START Midwest) and management is exploring pharmaceutical partnership opportunities and a potential NASDAQ dual listing to support future commercialization. The company holds 19 patent families across 11 jurisdictions and has raised approximately £41.5M over the past 18 months through equity placements and a convertible bond, with cash balances of £16.9M at year-end 2025.

Avacta serves two primary customer segments: (1) oncology patients with advanced solid tumors — including pancreatic, cervical/vulvar, gastric/GEJ, small cell lung, salivary gland, and soft tissue sarcoma cancers — who have exhausted standard treatment options and stand to benefit from targeted chemotherapy with reduced systemic toxicity; and (2) large pharmaceutical companies that may license or co-develop pre|CISION®-enabled candidates for broader commercialization. The go-to-market motion is enterprise field sales in nature, conducted via specialist clinical trial sites and through investor and scientific conference engagement (AACR, ESMO, EORTC-NCI-AACR, TD Cowen Healthcare Conference). Strategic collaboration with Tempus AI supports biomarker-driven indication selection, while intellectual property comprises 19 patent families covering both core platforms and program-specific applications.

Avacta Group firmographics

Firmographics
Name
Avacta Group
Legal name
Avacta Life Sciences Limited
Website
https://avacta.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Avacta Group plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing tumor-activated peptide drug conjugates for oncology using its proprietary pre|CISION® and Affimer® platforms. It targets advanced solid tumor patients through Phase 1 trials at US specialist oncology centers, with future revenue dependent on pharmaceutical licensing partnerships.
Ownership category
akta.pro rank

Avacta Group industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Peptide drug conjugates
  • Oncology drug development
  • Tumor-activated therapeutics
  • Biopharmaceutical pipeline
  • Targeted cancer therapy

Where Avacta Group is headquartered

Location

Headquarters

HQ city
Wetherby
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Avacta Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutics R&D: Pre-revenue clinical stage company. Generated £0.11 million in revenue from Therapeutics division in FY2025. Currently focused on advancing clinical pipeline through Phase 1 trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Avacta Group product offering

Product offering

Core offering

Avacta Group plc is a clinical-stage biopharmaceutical company developing oncology therapeutics based on two proprietary platforms: pre|CISION®, a tumor-activated drug delivery system that releases payloads at tumor sites via FAP cleavage, and Affimer®, a ~15kDa protein scaffold used for targeted biotherapeutics and drug conjugates. The pipeline consists of peptide drug conjugates including AVA6000 (doxorubicin PDC, Phase 1b), AVA6103 (exatecan PDC, Phase 1 FOCUS-01), and pre-clinical programs AVA6207 (dual payload), AVA7100 (AffDC), AVA3996 (proteasome inhibitor PDC), and AVA032 (Affimer-IL-15).

Product overview

Avacta Group is a pure-play oncology biopharmaceutical company developing a pipeline of peptide drug conjugates (PDCs) powered by two proprietary technology platforms: pre|CISION® and Affimer®. The pre|CISION® platform is a tumor-activated drug delivery technology that releases payloads exclusively at tumor sites via FAP enzyme cleavage. The Affimer® platform provides small protein scaffolds for biotherapeutic development. The current clinical pipeline includes Gen One AVA6000 (faridoxorubicin) in Phase 1b, Gen Two AVA6103 (FAP-Exd) in Phase 1, and Gen Three AVA6207 (dual payload) in pre-clinical development. Additional programs include AVA7100 and AVA3996. The company previously operated a diagnostics division (Launch Diagnostics and Coris Bioconcept) which has been divested as part of the transition to a pure-play therapeutics company.

Differentiator

Problem solved

Functional benefit

Brands

  • pre|CISION: Tumor-activated drug delivery platform that enables precise delivery of cytotoxic payloads directly to tumors, reducing systemic toxicity
  • Affimer
  • AffiDX
  • Faridoxorubicin (AVA6000)
  • FAP-Exd (AVA6103)

Products and services

  • pre|CISION® Platform

Quantifiable outcome

  • Nearly 3x higher Tumor Selectivity Index (TSI) compared to Enhertu® in preclinical studies
  • +3 more outcomes

Companies that use Avacta Group

Customer profile

Segments2 records

Ideal customer profiles2 records

Avacta Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Avacta Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • 3B BlackBio Dx LtdminorOthers · 29 August 2025Buyer of Coris Bioconcept SRL for £2.15 million upfront consideration with additional earn-out up to £0.615 million. Completion took place on August 29, 2025.
  • Duomed Belgium NV (Palex Healthcare Group)minorOthers · 25 March 2025Buyer of Launch Diagnostics Holdings Limited for £12.9 million. Completion took place in March 2025. Duomed is a subsidiary of Palex Healthcare Group S.L.U.
  • Tempus AIcoreStrategic or Co-development Partner · 30 October 2024Strategic collaboration using Tempus AI's data mining capabilities to investigate gene co-expression patterns (SLFN11 and FAP) for predicting cancer patient sensitivity to pre|CISION®-enabled therapies. This AI approach was used to select initial cancer indications for the FOCUS-01 Phase 1 trial of AVA6103.
  • Medusa Healthcare (Medusa 19 Healthcare)minorChannel Partner/ Reseller/ Distributor · 22 December 2021Exclusive arrangement with Medusa to commercialize the AffiDX® SARS-CoV-2 antigen lateral flow self-test product globally under the brand name MeduFlow. Medusa obtained CE mark for consumer self-testing.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Avacta Group competitors and assessment

Company assessment

Direct peers

  • Pyxis Oncology: Pyxis Oncology is a clinical-stage ADC company developing novel antibody-drug conjugates for solid tumors. It directly competes with Avacta's pre|CISION platform in the oncology targeted payload delivery space.
  • Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs) — a novel ADC-like platform that pairs tumor-targeted delivery with immune activation. As a clinical-stage platform oncology company, it overlaps with Avacta's strategy of using targeted delivery to enhance therapeutic index.
  • Mersana Therapeutics: Mersana develops next-generation ADCs using its Dolasynthen and Immunosynthen platforms, competing directly with Avacta's pre|CISION in oncology payload delivery. Both are clinical-stage oncology platform companies targeting solid tumors.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide drug conjugates (BCAs), a peptide-based targeted therapy platform analogous to Avacta's pre|CISION. Both companies use peptide scaffolds to deliver cytotoxic payloads with tumor selectivity, making them the closest direct peers in the PDC space.
  • ADC Therapeutics: ADC Therapeutics is a clinical and commercial-stage ADC company with Zynlonta approved for lymphoma and multiple pipeline candidates. It represents a directly competing ADC platform in the broader oncology drug conjugate space.
  • CytomX Therapeutics: CytomX develops Probody therapeutics, a conditionally activated antibody platform that is masked until activated by tumor-associated proteases. This shares Avacta's core concept of tumor-activated drug delivery, though using antibodies rather than peptides.
  • Ambrx Biopharma: Ambrx develops engineered antibody-drug conjugates using site-specific conjugation and novel payloads. Its platform approach to ADC development with engineered biologics is comparable to Avacta's AffDC (Affimer drug conjugate) strategy.

Broad incumbents

  • AbCellera Biologics: AbCellera is a large clinical-stage biologics discovery company with a proprietary antibody platform. While broader in scope, its technology platform approach (engineered antibodies for therapeutic applications) is comparable to Avacta's Affimer platform.
  • Daiichi Sankyo: Daiichi Sankyo is the global ADC leader with Enhertu (the benchmark Avacta uses for preclinical comparison). Its DXd ADC platform and deep oncology commercial infrastructure represent the dominant competitive force in the ADC market.

Emerging players

  • ProfoundBio: ProfoundBio is an early-stage ADC company developing next-generation conjugates with novel payloads and linkers. As a private oncology platform peer, it represents an emerging competitor in the targeted cancer therapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Avacta Group social profiles

Digital presence

Avacta Group compliance and trust

Trust signal

Compliance2 records

Avacta Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avacta Group leadership team

Management profile

Number of profiles

Profiles8 records

Avacta Group subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Avacta Group funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avacta Group M&A and investment

M&A and investment

M&A7 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avacta Group

What does Avacta Group do?

Avacta Group plc is a clinical-stage biopharmaceutical company developing oncology therapeutics based on two proprietary platforms: pre|CISION®, a tumor-activated drug delivery system that releases payloads at tumor sites via FAP cleavage, and Affimer®, a ~15kDa protein scaffold used for targeted biotherapeutics and drug conjugates. The pipeline consists of peptide drug conjugates including AVA6000 (doxorubicin PDC, Phase 1b), AVA6103 (exatecan PDC, Phase 1 FOCUS-01), and pre-clinical programs AVA6207 (dual payload), AVA7100 (AffDC), AVA3996 (proteasome inhibitor PDC), and AVA032 (Affimer-IL-15).

Is Avacta Group a public or private company?

Avacta Group is a public company. It is classified as public and is currently operating.

When was Avacta Group founded?

Avacta Group was founded in 2008. It employs 1 to 10 people.

Where is Avacta Group based?

Avacta Group is headquartered in Wetherby, United Kingdom, in the Europe region.

How does Avacta Group make money?

One revenue line is on record: therapeutics R&D.

Who are Avacta Group's main competitors?

Direct peers on record are Pyxis Oncology, Bolt Biotherapeutics, Mersana Therapeutics, Bicycle Therapeutics, ADC Therapeutics, CytomX Therapeutics and Ambrx Biopharma. Broad incumbents are AbCellera Biologics and Daiichi Sankyo. ProfoundBio is listed as an emerging player.

Does Avacta Group have an API?

No public API is recorded for Avacta Group.

What industry is Avacta Group in?

Avacta Group's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAvacta ESMO data show tumors recruit fibroblasts during treatment, boosting payload release capacityAvacta Group highlighted ESMO data showing tumors recruit fibroblasts during treatment, increasing their ability to release the payload. The findings have implications across the pre|CISION platform, informing how it works in the clinic.American Banking and Market NewsAvacta Group (OTCMKTS:AVCTF) Stock Falls 9.4% – Here’s What HappenedAvacta Group's stock fell 9.4% to $0.77 during mid-day trading on Thursday, with volume down 9% from average. The UK biotech company develops cancer therapies, including the doxorubicin prodrug AVA6000 and Affimer protein-binding technology.TradingViewREG - Avacta Group PLC - Highlights pre|CISION® Platform DataAvacta presented preclinical data and FOCUS-01 trial design for AVA6103 at ESMO, showing tumor response in Enhertu-resistant gastric tumors. The PDC platform recruits FAP+ fibroblasts for prolonged payload release, with first efficacy data expected in H1 2027.Seeking AlphaAvacta Group Plc (AVCTF) Q2 2026 Earnings Call TranscriptAvacta Group reported its Q2 2026 interim results, highlighting its pre|CISION platform, a tumor-activated peptide drug conjugate. The company's lead asset, FAP exatecan (AVA6103), is a controlled-release version of exatecan designed to widen the therapeutic index by targeting FAP-expressing solid tumors.Investing.comAvacta to present cancer drug trial data at ESMO congressAvacta Therapeutics will present data from its Phase 1a trial of Faridoxorubicin and the design of its FOCUS-01 trial at the ESMO congress in Madrid from October 23-27. The company will deliver two poster presentations, including progression-free survival data and FAPI-PET imaging results.American Banking and Market NewsAvacta Group (OTCMKTS:AVCTF) Shares Down 9% – Here’s WhyAvacta Group shares fell 9% on Wednesday, trading as low as $0.8535, with volume dropping 100% from average. The UK life sciences firm, developing targeted cancer treatments, had previously closed at $0.9376.InvestegateCapital Access Window - Avacta Group PlcAvacta Group's ordinary shares trading on AIM was restored from 06 October 2026 at 7:30 am after a Capital Access Window closed. The company completed necessary actions, which may affect investor confidence and share price movement.YahooAvacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business UpdateAvacta reported H1 2026 interim results with revenue of £0.06 million and an operating loss of £13.91 million. Cash and short-term deposits stood at £20.27 million as of June 30, 2026, and the company announced a proposed capital raise. First efficacy data for AVA6103 is expected in H1 2027.Investing.comStock Market News - Investing.com IndiaAvacta Group announced that its pre|CISION platform won the Research and Development Achievement Award from the Pharma Industry Awards UK 2026. The company's first candidate, AVA6103, has entered clinical trials in the FOCUS-01 study, with patient enrollment ongoing.Investing.comStock Market News - Investing.com IndiaAvacta Group presented the FOCUS-01 trial design and preclinical data for AVA6103, a peptide-drug conjugate targeting pancreatic ductal adenocarcinoma, at a conference in San Diego. The Phase 1a trial is enrolling patients with select tumor types, with preliminary safety data showing the drug was well tolerated up to a payload dose 50% higher than conventional exatecan. The company expects an initial efficacy readout in the first half of 2027.